Literature DB >> 21553400

Understanding patient compliance and persistence with osteoporosis therapy.

Deborah T Gold1.   

Abstract

Chronic non-terminal diseases, including postmenopausal osteoporosis, are associated with poor treatment compliance and persistence. The longer a patient with osteoporosis complies and persists with treatment, the lower the risk of fracture. Retrospective studies with emphasis on real-world data have led to a greater understanding of the factors affecting medication compliance and persistence, and their association with improved treatment outcomes. However, these data do not contain information about patient choices of medication or patient commitment to particular medication regimens. Patient preferences can affect compliance and persistence behaviours. While recent evidence questions the importance of dosing regimen in patient preferences, other recent data show that medication efficacy and safety remain the most important determinants of patient preference. Informed patient decision making about treatment options, adverse effects and outcomes can have a beneficial impact on medication-taking behaviour. Healthcare professionals play a crucial role in the management of factors associated with poor compliance and persistence with osteoporosis therapies. Education about disease consequences and differences among treatment options, as well as treatment monitoring and positive reinforcement, are crucial to improving medication compliance and persistence in osteoporotic patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553400     DOI: 10.2165/11586880-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  44 in total

Review 1.  Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?

Authors:  Sheila A Doggrell
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

2.  Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.

Authors:  Timothy W Downey; Susan H Foltz; Stephen J Boccuzzi; Mohamed A Omar; Kristijan H Kahler
Journal:  South Med J       Date:  2006-06       Impact factor: 0.954

3.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

4.  An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study.

Authors:  Thomas W Weiss; Deborah T Gold; Stuart L Silverman; Colleen A McHorney
Journal:  Curr Med Res Opin       Date:  2006-05       Impact factor: 2.580

5.  Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.

Authors:  Fernie J A Penning-van Beest; Wim G Goettsch; Joëlle A Erkens; Ron M C Herings
Journal:  Clin Ther       Date:  2006-02       Impact factor: 3.393

6.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

7.  Early discontinuation of treatment for osteoporosis.

Authors:  Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger
Journal:  Am J Med       Date:  2003-08-15       Impact factor: 4.965

8.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

9.  Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.

Authors:  J T Harrington; L-G Ste-Marie; M L Brandi; R Civitelli; P Fardellone; A Grauer; I Barton; S Boonen
Journal:  Calcif Tissue Int       Date:  2003-12-05       Impact factor: 4.333

10.  Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.

Authors:  A Cooper; J Drake; E Brankin
Journal:  Int J Clin Pract       Date:  2006-06-19       Impact factor: 2.503

View more
  5 in total

1.  Bone care nurses and the evolution of the nurse's educational function: the Guardian Angel(®) research project.

Authors:  Rosaria Alvaro; Annalisa Pennini; Emanuela Basilici Zannetti; Noemi Cittadini; Maurizio Feola; Cecilia Rao; Fabio D'Agostino; Ercole Vellone; Umberto Tarantino
Journal:  Clin Cases Miner Bone Metab       Date:  2015 Jan-Apr

2.  Adherence to therapies in patients with type 2 diabetes.

Authors:  Luis-Emilio García-Pérez; María Alvarez; Tatiana Dilla; Vicente Gil-Guillén; Domingo Orozco-Beltrán
Journal:  Diabetes Ther       Date:  2013-08-30       Impact factor: 2.945

3.  The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy.

Authors:  Ewa Sewerynek; Hanna Horst-Sikorska; Wioletta Stępień-Kłos; Agnieszka Antkowiak; Małgorzata Janik; Karol Cieślak; Michalina Marcinkowska; Agnieszka Cegłowska; Michał Stuss
Journal:  Arch Med Sci       Date:  2013-04-22       Impact factor: 3.318

4.  Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?

Authors:  Tracey-Lea Laba
Journal:  Arthritis Res Ther       Date:  2014-03-10       Impact factor: 5.156

5.  Patient-Related Factors Associated with Adherence to Recommendations Made by a Fracture Liaison Service: A Mixed-Method Prospective Study.

Authors:  Mireille Luc; Hélène Corriveau; Gilles Boire; Johanne Filiatrault; Marie-Claude Beaulieu; Isabelle Gaboury
Journal:  Int J Environ Res Public Health       Date:  2018-05-09       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.